Oncolytics Biotech, Inc (NASDAQ:ONCY) price on current trading day, rose 17.76% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.59.
A look at the stock’s price movement, the level at last check in today’s session was $0.50, moving within a range at $0.5002 and $0.6362. The beta value (5-Year monthly) was 1.546. Turning to its 52-week performance, $1.53 and $0.47 were the 52-week high and 52-week low respectively. Overall, ONCY moved -5.47% over the past month.
Oncolytics Biotech, Inc’s market cap currently stands at around $50.89 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-06.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ONCY is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend ONCY as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ONCY’s current price about 2.92% and -10.15% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 50.09, while 7-day volatility ratio is 11.14% and 6.28% in the 30-day chart. Further, Oncolytics Biotech, Inc (ONCY) has a beta value of 1.01, and an average true range (ATR) of 0.04.
If we refocus on Oncolytics Biotech, Inc (NASDAQ:ONCY), historical trading data shows that trading volumes averaged 0.29 over the past 10 days and 1.05 million over the past 3 months. The company’s latest data on shares outstanding shows there are 86.42 million shares.
The 1.80% of Oncolytics Biotech, Inc’s shares are in the hands of company insiders while institutional holders own 1.53% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 3.0 million on 2025-03-14, giving us a short ratio of 9.7. The data shows that as of 2025-03-14 short interest in Oncolytics Biotech, Inc (ONCY) stood at 361.0 of shares outstanding, with shares short falling to 3.05 million registered in 2025-02-14. Current price change has pushed the stock -35.55% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ONCY stock continues to rise going into the next quarter.
